Collagenex, Mutual Settle Patent Suit Over Periodontitis Treatment

Law360, New York (April 10, 2004, 12:00 AM EDT) -- CollaGenex Pharmaceuticals has settled its patent litigation against Mutual Pharmaceuticals over a treatment for adult periodontitis, in an agreement that includes a licensing agreement and a $2 million payment to Mutual.

As part of the settlement, CollaGenex and Mutual entered into a licensing agreement giving Mutual a license to sell a branded version of Periostat. CollaGenex will be the sole supplier of this product to Mutual at prices below CollaGenex's average manufacturer's price through May 2007 or the earlier termination of such supply arrangements due to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.